How Translational Central Lab Services Facilitate Creative Solutions For Biomarker-Driven Studies

Biomarker-driven clinical trials are increasingly becoming the standard approach in medical research. Between 2019 and 2022, 16.5% of all clinical trials and nearly half of oncology studies incorporated biomarkers. Despite their advantages, the translation of biomarkers into clinical practice is often complex and demands meticulous planning. Successful execution of a biomarker-driven study involves numerous considerations, such as selecting appropriate biomarkers, determining measurement methods, validating assays, and assessing the feasibility of integrating these assays into clinical trials. This article delves into the critical role of planning in biomarker clinical research, as well as addresses common operational and scientific challenges encountered in translational studies to emphasize the importance of strategic planning.